$287 Million is the total value of COMMODORE CAPITAL LP's 29 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 55.6% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CLDX | Sell | CELLDEX THERAPEUTICS INC NEW | $10,816,000 | +41.9% | 323,437 | -12.6% | 3.77% | +24.1% |
| VTGN | Sell | VISTAGEN THERAPEUTICS INC | $10,494,000 | +32.1% | 3,331,315 | -10.7% | 3.66% | +15.5% |
| PTGX | Sell | PROTAGONIST THERAPEUTICS INC | $9,452,000 | +4.4% | 210,600 | -39.8% | 3.29% | -8.7% |
| DYN | Sell | DYNE THERAPEUTICS INC | $6,420,000 | -3.9% | 305,125 | -29.1% | 2.24% | -15.9% |
| LSAQ | Exit | LIFESCI ACQUISITION II CORP | $0 | – | -100,000 | -100.0% | -0.40% | – |
| SNDX | Exit | SYNDAX PHARMACEUTICALS INC | $0 | – | -236,500 | -100.0% | -2.11% | – |
| RLMD | Exit | RELMADA THERAPEUTICS INC | $0 | – | -161,565 | -100.0% | -2.27% | – |
| Exit | TRILLIUM THERAPEUTICS INC | $0 | – | -795,868 | -100.0% | -3.40% | – | |
| FPRX | Exit | FIVE PRIME THERAPEUTICS INC | $0 | – | -361,344 | -100.0% | -5.42% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR/A filed 2021-10-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| XENON PHARMACEUTICALS INC | 12 | Q3 2023 | 10.3% |
| COGENT BIOSCIENCES INC | 12 | Q3 2023 | 10.4% |
| VIRIDIAN THERAPEUTICS INC | 11 | Q3 2023 | 8.9% |
| CYMABAY THERAPEUTICS INC | 11 | Q2 2023 | 5.4% |
| KURA ONCOLOGY INC | 11 | Q3 2023 | 7.1% |
| CELLDEX THERAPEUTICS INC NEW | 11 | Q3 2023 | 3.8% |
| ACLARIS THERAPEUTICS INC | 10 | Q1 2023 | 10.4% |
| CELCUITY INC | 10 | Q3 2023 | 7.3% |
| KALVISTA PHARMACEUTICALS INC | 10 | Q2 2023 | 2.2% |
| MERUS N V | 9 | Q3 2023 | 12.5% |
View COMMODORE CAPITAL LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | April 27, 2023 | 31,181,983 | 8.1% |
| BELLUS Health Inc. | March 30, 2023 | 6,579,359 | 5.2% |
| IMARA Inc. | February 21, 2023 | 2,840,754 | 10.8% |
| Karyopharm Therapeutics Inc. | February 14, 2023 | 1,935,609 | 1.7% |
| VistaGen Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Satsuma Pharmaceuticals, Inc.Sold out | November 16, 2022 | 0 | 0.0% |
| GENOCEA BIOSCIENCES, INC. | February 14, 2022 | 3,079,756 | 5.4% |
View COMMODORE CAPITAL LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| SC 13G | 2024-04-19 |
| SC 13G | 2024-03-21 |
| 13F-HR/A | 2024-02-14 |
| 13F-HR | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
| SC 13G/A | 2024-02-14 |
View COMMODORE CAPITAL LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.